Vemurafenib prodrug - HEC Pharm
Latest Information Update: 03 Nov 2015
At a glance
- Originator HEC Pharm
- Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Proto oncogene protein b raf inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 03 Nov 2015 Preclinical trials in Malignant melanoma in China (unspecified route) (HEC Pharm, October 2015)